3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
CNS
1
Conditions
Squamous Cell Carcinoma of Head and Neck
3
Melanoma
3
Recurrence
2
Head and Neck Neoplasms
2
Carcinoma, Renal Cell
2
Triple Negative Breast Neoplasms
1
Skin Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Neuroblastoma
1
Neoplasms
1
Neoplasm Metastasis
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Kidney Neoplasms
1
Glioma
1
Ependymoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Interventions
Vincristine
2
Temozolomide
2
Irinotecan
2
Doxorubicin
2
Cyclophosphamide
2
Bone Marrow Transplantation
2
robatumumab
1
pegfilgrastim
1
palbociclib
1
lexatumumab
1
ganitumab
1
disaccharide tripeptide
1
delta 24-sterol reductase
1
copanlisib
1
bempegaldesleukin
1
Thiotepa
1
Radiosurgery
1
Plicamycin
1
Peripheral Blood Stem Cell Transplantation
1
Nivolumab
1
Melphalan
1
Magnetic Resonance Spectroscopy
1
Interferon-gamma
1
Immunotherapy, Adoptive
1
INCB059872
1
IL32 protein, human
1
Granulocyte Colony-Stimulating Factor
1
Genistein
1
Filgrastim
1
FANG vaccine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Sarcoma, Ewing
×
bempegaldesleukin
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts